Newsletter

BioMedSA’s Board of Directors approved 4 new memberships in September 2024: Accela Advisors, Archer Agency, Guido Construction, and NovoThelium. Accela Advisors provides multidisciplined consulting for emerging pharma, biotech and medical device companies. The foundation is the work and experience of Mike Sember a seasoned executive, investor and mentor and specializes in strategic planning, business development … Read more

For almost 2 decades, BioMedSA has presented the Award for Innovation in Healthcare and Bioscience to recognize impactful work from national, regional and local drivers in the field; including patient care, education, research and development, leadership, public policy and medical technology. This premier event provides opportunities to expand visibility, connect with healthcare and biomedical leaders … Read more

Businesses who intend to seek venture capital investment often choose to be a Delaware Corporation. Why? According to Delaware.gov, “More than one million business entities take advantage of Delaware’s complete package of incorporation services, including modern and flexible corporate laws, our highly-respected Judiciary and legal community, a business-friendly government, and the customer-service-oriented staff of the … Read more

Dr. Brett Ginsburg, Ph.D., a distinguished professor in the Department of Psychiatry and Behavioral Science at the Joe R. and Teresa Lozano Long School of Medicine, is a prominent researcher in pharmacology and behavioral neurobiology. His research has focused on neurobiological mechanisms in alcoholism recovery, effects of synthetic cannabinoids and acute intoxication stress treatments, opioid … Read more

Advancing biologics through commercialization is a long process. Traditional funding routes such Initial public offerings (IPO) are less common, venture capital and private equity firms can be more selective, and the mergers & acquisition (M&A) option isn’t always available for pre-clinical and early-stage companies. Fortunately, traditional funding routes are not the only options for advancing … Read more

Gregory C. Ippolito, Ph.D. brings deep expertise in approaches that reveal fundamental mechanisms of a body’s immune response to infection, as well as responses where antibodies mistakenly attack healthy organs and tissues in autoimmune disorders such as lupus. He and collaborators have identified antibody repertoires elicited by vaccines or treatments. They designed a protocol that … Read more

Paolo Casali, M.D. has spent almost 5 decades in the areas if immunology, microbiology and molecular genetics. Dr. Casali studies how certain genes are turned on or off in the immune system and looks at how these changes affect the body’s ability to make antibodies; proteins that help fight infections. The Casali lab studies how … Read more

BioMedSA’s Board of Directors approved 4 new memberships in June 2024: Eppendorf, Lone Star National Bank, Pizarro Allen, and Raven Innovations. Eppendorf is a German based company that seeks to support research in academic, commercial, and industrial spaces by developing and manufacturing a variety of products and services for use in laboratories in pharmaceutical, biotech, … Read more

Dr. Alison Wiesenthal is the current Chair of the Department of Rehabilitation Medicine at Brooke Army Medical Center (BAMC). Stepping into this role in March of 2020, Wiesenthal became the first civilian to hold the position. She founded the first interdisciplinary Palliative Care Service to the Department of Defense in 2017. Her current role also … Read more

Dr. Laurence Morel is investigating the mechanisms of lupus pathogenesis. The ultimate goal of her work is to establish better clinical management and therapeutic targets by identifying lupus susceptibility in genes or pathways.  Her current focus is CD4 T cells and B cells. In 2022, the University of Texas System awarded Dr. Morel $1.4M to establish … Read more